Dar? Bioscience, Inc. - SIC # 3850 -

Ticker Exchange SIC # Website Latest Ticker
DARE Nasdaq 3850 darebioscience.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Dar? Bioscience, Inc.

Top Midday Gainers - Jul 14th, 2025 11:56 am
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive - Jul 14th, 2025 6:00 am
Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders - Jul 11th, 2025 6:00 am
Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders - Jun 12th, 2025 3:00 pm
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Jun 6th, 2025 7:40 am
Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream - Jun 4th, 2025 6:00 am
Dare Bioscience Inc (DARE) Q1 2025 Earnings Call Highlights: Strategic Expansions and Cost ... - May 14th, 2025 1:14 am
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates - May 13th, 2025 3:10 pm
Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update - May 13th, 2025 2:01 pm
Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025 - May 6th, 2025 6:00 am
Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women’s Health Innovation - Apr 23rd, 2025 6:00 am
Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year - Apr 7th, 2025 6:00 am
Dare Bioscience Inc (DARE) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial ... - Apr 1st, 2025 1:03 am
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates - Mar 31st, 2025 3:15 pm
Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update - Mar 31st, 2025 2:01 pm
Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025 - Mar 24th, 2025 6:00 am
Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant - Feb 20th, 2025 6:00 am
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development - Feb 6th, 2025 6:00 am
Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference - Jan 9th, 2025 6:00 am
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) - Dec 16th, 2024 6:00 am